Literature DB >> 23462913

Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large German prospective cohort study.

José M Ordóñez-Mena1, Ben Schöttker, Ulrike Haug, Heiko Müller, Josef Köhrle, Lutz Schomburg, Bernd Holleczek, Hermann Brenner.   

Abstract

BACKGROUND: Several observational studies assessed the relationship between serum 25-hydroxyvitamin D [25(OH)D] concentrations and the risk of cancer but results were inconclusive.
METHODS: We measured 25(OH)D concentrations in a population-based cohort study of 9,949 men and women ages 50 to 74 years in Saarland, Germany. Comprehensively adjusted Cox regression models were applied to estimate HRs and 95% confidence intervals (CI) for the association between season-standardized 25(OH)D concentrations and total and site-specific cancer incidence.
RESULTS: Overall, during a median of 8 years of follow-up, 873 subjects developed cancer; the most common being prostate (171), breast (137), lung (136), and colorectal (136) cancer. Low season-standardized 25(OH)D (<30, 35, 40, or 36 nmol/L in winter, spring, summer, and autumn, respectively) was neither significantly associated with total cancer incidence (HR, 1.10; 95% CI, 0.93-1.30) nor with site-specific cancer incidence. However, a significantly increased overall cancer risk was observed for low 25(OH)D among men, nonobese subjects and subjects reporting low fish consumption and for high 25(OH)D in nonsmokers and nonobese subjects. Accordingly, restricted cubic splines to investigate dose-response relationships curves showed an inverse association of 25(OH)D levels and total cancer risk in men but not in women.
CONCLUSIONS: 25(OH)D concentrations were significantly associated with overall cancer incidence in subgroups of this large cohort from Germany. No significant association was observed with site-specific cancers but this could be due to a limited statistical power for these endpoints. IMPACT: Further research should clarify whether and to what extent specific risk groups might profit from vitamin D supplementation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23462913     DOI: 10.1158/1055-9965.EPI-12-1332

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  36 in total

1.  Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Stephanie J Weinstein; Mark P Purdue; Stephanie A Smith-Warner; Alison M Mondul; Amanda Black; Jiyoung Ahn; Wen-Yi Huang; Ronald L Horst; William Kopp; Helen Rager; Regina G Ziegler; Demetrius Albanes
Journal:  Int J Cancer       Date:  2014-09-02       Impact factor: 7.396

2.  Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies.

Authors:  Dan Wang; Omar Israel Vélez de-la-Paz; Jun-Xia Zhai; Dian-Wu Liu
Journal:  Tumour Biol       Date:  2013-06-27

3.  Circulating Vitamin D Levels and Risk of Colorectal Cancer in Women.

Authors:  Paulette D Chandler; Julie E Buring; JoAnn E Manson; Edward L Giovannucci; M V Moorthy; Shumin Zhang; I-Min Lee; Jennifer H Lin
Journal:  Cancer Prev Res (Phila)       Date:  2015-03-26

4.  Pre-diagnostic vitamin D concentrations and cancer risks in older individuals: an analysis of cohorts participating in the CHANCES consortium.

Authors:  José Manuel Ordóñez-Mena; Ben Schöttker; Veronika Fedirko; Mazda Jenab; Anja Olsen; Jytte Halkjær; Ellen Kampman; Lisette de Groot; Eugene Jansen; H Bas Bueno-de-Mesquita; Petra H Peeters; Galatios Siganos; Tom Wilsgaard; Laura Perna; Bernd Holleczek; Ulrika Pettersson-Kymmer; Philippos Orfanos; Antonia Trichopoulou; Paolo Boffetta; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2015-05-15       Impact factor: 8.082

5.  A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Authors:  Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey
Journal:  J Oncol Pharm Pract       Date:  2014-07-01       Impact factor: 1.809

6.  Is vitamin D deficiency a cause of increased morbidity and mortality at older age or simply an indicator of poor health?

Authors:  Ben Schöttker; Kai-Uwe Saum; Laura Perna; José Manuèl Ordóñez-Mena; Bernd Holleczek; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2014-03-29       Impact factor: 8.082

7.  Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis.

Authors:  Yonghua Xu; Xiaoping Shao; Yacheng Yao; Lijian Xu; Liang Chang; Zhuojuan Jiang; Zhaofen Lin
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-17       Impact factor: 4.553

8.  Associations of serum 25-hydroxyvitamin D level with incidence of lung cancer and histologic types in Norwegian adults: a case-cohort analysis of the HUNT study.

Authors:  Yi-Qian Sun; Arnulf Langhammer; Chunsen Wu; Frank Skorpen; Yue Chen; Tom Ivar Lund Nilsen; Pål Richard Romundstad; Xiao-Mei Mai
Journal:  Eur J Epidemiol       Date:  2017-10-27       Impact factor: 8.082

9.  Plasma 25-hydroxy vitamin D and subsequent prostate cancer risk in a nested Case-Control study in Japan: The JPHC study.

Authors:  N Sawada; M Inoue; M Iwasaki; T Yamaji; T Shimazu; S Sasazuki; S Tsugane
Journal:  Eur J Clin Nutr       Date:  2016-10-19       Impact factor: 4.016

10.  Serum 25-hydroxyvitamin D concentrations and lung cancer risk in never-smoking postmenopausal women.

Authors:  Ting-Yuan David Cheng; Xiaoling Song; Shirley A A Beresford; Gloria Y F Ho; Karen C Johnson; Mridul Datta; Rowan T Chlebowski; Jean Wactawski-Wende; Lihong Qi; Marian L Neuhouser
Journal:  Cancer Causes Control       Date:  2017-09-12       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.